Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Phase I clinical trial of novel analgesic to begin in Sweden

May 13, 1998

Phase III trials in progress for HMR antipsychotic agent

May 13, 1998

Pharmacia & Upjohn submits NDA for Edronax

May 12, 1998

Actiq trial results published; NDA amendment filed

May 11, 1998

Rasagiline demonstrates neuroprotective effects on dopaminergic neurons

May 11, 1998

Enzyme inhibitors useful for neurodegenerative disorders prepared at P&U

May 11, 1998

Rebif reduces disease activity in patients with MS

May 8, 1998

New GABA-B antagonist shows memory-enhancing effects in rats

May 8, 1998

Novel glutamate receptor antagonists in development at Warner-Lambert

May 8, 1998

Benzodiazepine agonists and their use described by Synthelabo

May 8, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.